Gemcitabine/carboplatin in advanced non-small cell lung cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023841%3A_____%2F02%3A00005571" target="_blank" >RIV/00023841:_____/02:00005571 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Gemcitabine/carboplatin in advanced non-small cell lung cancer
Original language description
Gemcitabine/cisplatin is among the most widely used regimens inEurope for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologie toxicity and difficulty of use in outpatiCarboplatin constitutes a reasonable alternative to cisplatin in this combination, since it showa synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematolgic toxicity profile. Studies of gemcitabine/cisplation a 28-day shedule (e.g. gemcitabine on days 1, 8, 15 and carboplatin on day 1)generally indicate excessive thrompocytopenia. Use of 21 day shedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity andcomparable efficiacy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NC6070" target="_blank" >NC6070: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in non-small cell lung cancer stage IIIB and IV. A randomized study.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2002
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)